Rana R. McKay, MD, University of California, San Diego
Articles by Rana R. McKay, MD, University of California, San Diego
Rana R. McKay, MD, discusses unmet needs in mCRPC that led to the inception of the COMRADE trial.
Rana R. McKay, MD, FASCO, discusses the safety profiles of olaparib plus radium-223 vs radium-223 monotherapy in mCRPC.
Rana R. McKay, MD, FASCO, discusses data the combination of olaparib plus radium-223 vs radium-223 monotherapy in castration-resistant prostate cancer.
Metastatic CRPC: Novel Treatment Strategies With Radioligand Therapy
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Key opinion leaders share insight to novel combination strategies and clinical trials focused on radioligand therapy in metastatic castration-resistant prostate cancer.
Radioligands in the Treatment of Metastatic CRPC: Radium-223
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Continuing their segment on radioligand therapy in metastatic castration-resistant prostate cancer, panelists highlight data behind use of radium-223.
Radioligands in the Treatment of Metastatic CRPC: Lutetium-177–PSMA-617
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Focused discussion on the role of lutetium-177–PSMA-617 as radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Combination PARPi Strategies in Metastatic CRPC: Interpreting Data From Clinical Trials
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Key opinion leaders in metastatic castration-resistant prostate cancer management review a subset of clinical trials focused on combination strategies with PARP inhibitors.
Advent of PARP Inhibitors in Metastatic CRPC
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.
Evolving Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Comprehensive insight to key treatment modalities for patients with nonmetastatic castration-resistant prostate cancer and how to select amongst them.
Informing Systemic Therapy Selection With Negative Data in HSPC
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD A brief conversation on negative clinical trial readouts and how they may help to inform optimal treatment pathways for patients with metastatic hormone-sensitive prostate cancer.
What is the Role of Locoregional Therapy in Metastatic HSPC?
ByRana R. McKay, MD, University of California, San Diego,Arash Rezazadeh Kalebasty, MD ,Sumit K. Subudhi, MD, PhD,Scott T. Tagawa, MD, MS, FACP, New York-Presbyterian Hospital & Weill Cornell Medical College,Ulka Vaishampayan, MD Following their discussion on systemic therapy, expert panelists consider the value of locoregional therapy for a subset of patients with metastatic hormone-sensitive prostate cancer.
Rana R. McKay, MD, discusses the pros and cons of utilizing triplet therapy in the frontline treatment of patients with renal cell carcinoma.
Rana R. McKay, MD, discusses four key trials that have advanced the frontline treatment of metastatic renal cell carcinoma in the modern era.
Rana R. McKay, MD, discusses the outcomes of landmark clinical trials in frontline renal cell carcinoma.
Final Thoughts on the Management of mRCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
Additional Emerging Therapies for Progressive mRCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
Emerging Agents for Progressive mRCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
Sequencing After Frontline I/O Based Regimen for mRCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
Clinical Trials for Relapsed/Refractory mRCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
Upcoming Combination Trials for mRCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
I/O Therapy After Progression on I/O for mRCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
Role of TKI After Progression on I/O for mRCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
Review of the COSMIC 021 Study for mRCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
Introduction and Review of CheckMate 9ER for Metastatic RCC
ByToni Choueiri, MD, Dana-Farber Cancer Institute,Rana R. McKay, MD, University of California, San Diego,Nizar M. Tannir, MD, FACP, MD Anderson Cancer Center,Martin H. Voss, MD, Memorial Sloan Kettering Cancer Center,Bernard Escudier, MD, Institut Gustave Roussy 
Advent of PARP Inhibitors in Metastatic CRPC
Radioligands in the Treatment of Metastatic CRPC: Radium-223
Dr McKay on Data for Olaparib Plus Radium-223 in CRPC With Bone Metastases
Rapid Readouts: Phase 3 CheckMate 9ER Trial
What is the Role of Locoregional Therapy in Metastatic HSPC?